BTK and Schwartz-Jampel syndrome: However, there have been no reports of severe drug eruptions such as SJS/TEN with ibrutinib, a different BTK inhibitor, and most reports involve drug eruptions with distinct features from those associated with tirabrutinib, such as neutrophilic dermatosis.10 This may be due to the fact that tirabrutinib is a more selective BTK inhibitor, potentially making it more prone to triggering immune responses via BTK pathways.